Application of a star-shaped glial cell KCNQ3 siRNA vesicle in the preparation of a drug for treating, preventing or relieving stroke
By targeting and delivering interfering RNA via KCNQ3 siRNA vesicles in astrocytes, knocking down or eliminating KCNQ3 channels within astrocytes, the problem of insufficient neuronal regulation in current stroke treatments has been solved, achieving the effects of reducing cerebral ischemia area and improving motor cognitive function.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- HEBEI MEDICAL UNIVERSITY
- Filing Date
- 2026-04-21
- Publication Date
- 2026-07-17
AI Technical Summary
Current stroke treatments are insufficient in regulating neuronal excitability, and systemic administration may affect other organ systems. No studies have explored regulatory strategies for KCNQ3 channels in astrocytes to block secondary damage.
Using KCNQ3 siRNA vesicles from astrocytes, drugs for the treatment, prevention, or relief of stroke can be prepared by delivering interfering RNA to knock down or eliminate KCNQ3 channels in astrocytes. The vesicles can penetrate the blood-brain barrier and specifically target astrocytes.
It significantly reduced the area of cerebral ischemia in model mice and improved the motor and cognitive functions of ischemic mice, providing a basis for preclinical research and laying an important foundation for the preparation of drugs to treat stroke.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3